Sachin Kamal-Bahl is currently Vice President and Head of the Global Health and Value Innovation Center at Pfizer Inc. — a newly created organization under Dr Kamal-Bahl’s leadership — that develops and integrates innovative approaches based on well-considered risks and strong technical underpinnings to address the access, pricing or valuation of challenges and opportunities. Dr Kamal-Bahl oversees the group’s strategic efforts aimed to a) help the organization recognize the strategic implications of environmental issues impacting valuation of and access to Pfizer therapies; b) develop and test prototypes and consider systematically embedding them within internal processes of the organization in order to better position Pfizer to demonstrate value and gain market access for assets at launch; c) develop, execute and evaluate innovative experimental approaches in order to address access, pricing or valuation challenges for Pfizer assets being raised by payers and; d) spearhead efforts with strong technical underpinnings to develop and/or support Pfizer’s approach to access, value and shape external practices over time.
Dr. Kamal-Bahl previously was the Executive Director and Global HTA Strategy Head at Merck & Co., Inc., where he provided strategic guidance to senior leadership on aspects related to HTA and its evolving landscape and was responsible for the development of Merck’s positions on key HTA topics. His group was also responsible for translating and executing HTA concepts across all of Merck’s franchises and geographies/regions.
Prior to this role, Dr. Kamal-Bahl was the Global Access Team Leader for the Diabetes and Obesity Franchise in the Global Market Access division at Merck & Co., Inc. In this key strategic role he led a companywide global cross-functional team that was responsible for developing an integrated market access strategy that includes pricing, reimbursement, health economics and outcomes research, health technology assessment, and payer and stakeholder engagement strategies to optimize profitability and market access and coordinate the implementation of this strategy for the entire portfolio of products under the Diabetes and Obesity Franchise.
In other previous roles within the company, Dr. Kamal-Bahl has worked in the Global Strategic Pricing area where he was a Global Strategic Pricing Leader responsible for developing the pricing strategies for all products under the diabetes and obesity franchise. In the past he has also led the development of health economics, outcomes research, market access and reimbursement strategies supporting the cardiovascular and metabolic franchises in leveraging the value proposition for cardiovascular, diabetes and obesity products within the US Outcomes Research & Management and Global Outcomes Research departments at Merck & Co., Inc.
Dr. Kamal-Bahl is a clinically trained pharmacist who obtained a Ph.D. in pharmaceutical health services research at the University of Maryland, Baltimore, MD. He currently also holds positions as Adjunct Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania and as Adjunct Assistant Professor at the University of Maryland School of Pharmacy.
Dr. Kamal-Bahl is actively involved with several professional organizations such as AcademyHealth, American Heart Association, American Diabetes Association and International Society for Pharmacoeconomics and Outcomes Research. He has also published in several journals such as American Journal of Cardiology, American Heart Journal, Archives of Internal Medicine, Archives of Pediatrics and Adolescent Medicine, Diabetes Care, Endocrine Practice, Health Affairs, International Journal of Obesity, Journal of the American Geriatrics Society, Obesity, and Preventing Chronic Disease.